News

Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV
Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
The launch of the injection faces potential threats, including the Trump administration's proposed cuts to federal funding ...
FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
KSL13h
FDA approves HIV drug based on University of Utah biochemist's findings
Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...
U.S. approves first-ever biannual shot to prevent HIV, but getting it might be hard
WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...
STAT5d
HIV protection with just two shots a year: FDA approves Gilead drug
A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...
Gilead’s Twice-a-Year HIV Prevention Shot Wins FDA Approval
Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a ...
The FDA Just Approved a Long-Lasting Injection to Prevent HIV
Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...
STAT6d
Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access?
Now that Gilead Sciences has won U.S. regulatory approval for its groundbreaking HIV prevention drug, the company has another hurdle to clear — ensuring the medicine can be accessed in low ...
FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag
Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...
BioSpace13d
Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
NIH office to phase out HIV guidelines by next year
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...